Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human thrombopoietin + intravenous immunoglobulin + methylprednisolone
- Development stage
- Unknown
- Lead developer
- CSL Behring
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
The combination of recombinant human thrombopoietin (rhTPO), intravenous immunoglobulin (IVIG), and methylprednisolone is a multi-modality therapeutic regimen used primarily for the emergency or frontline management of severe, refractory, or life-threatening immune thrombocytopenia (ITP). This triple combination addresses ITP through complementary mechanisms: rhTPO stimulates megakaryocytopoiesis and platelet production by binding to the thrombopoietin receptor (MPL); IVIG rapidly blocks Fc-receptor-mediated platelet clearance by splenic macrophages; and methylprednisolone, a potent glucocorticoid, suppresses the underlying autoimmune response and reduces autoantibody production. This regimen is particularly utilized in clinical scenarios requiring rapid platelet recovery, such as severe bleeding episodes, preparation for urgent surgery, gestational ITP, or immune checkpoint inhibitor-induced thrombocytopenia.
- Other names
- IVIG + methylprednisolone + recombinant human thrombopoietinIVIG + methylprednisolone + rhTPOintravenous immunoglobulin + methylprednisolone + recombinant human thrombopoietinmethylprednisolone + intravenous immunoglobulin + recombinant human thrombopoietinrecombinant human thrombopoietin + IVIG + methylprednisolonerhTPO + IVIG + methylprednisolonerhTPO + intravenous immunoglobulin + methylprednisolone
02
Targets
GR (Glucocorticoid receptor)FCGR1A (High affinity immunoglobulin gamma fc receptor I)FCGRT (Neonatal crystallizable fragment receptor)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)FCGR2B (Fc gamma receptor IIB)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on recombinant human thrombopoietin + intravenous immunoglobulin + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human thrombopoietin + intravenous immunoglobulin + methylprednisolone.